ストックスクリーナーアプリを入手
1.76
3.85%
0.07
Annovis Bio Inc (ANVS) 最新ニュース
Annovis Completes Enrollment for Alzheimer’s Phase 3 Trial - MyChesCo
Annovis Bio enrolls over 850 patients for its next Alzheimer's Disease trial - qz.com
Annovis Bio Completes Enrollment for Pivotal Phase 3 Alzheimer’s Trial, Plans NDA Submissions in 2027 and 2028 12 - Minichart
Annovis Bio Completes Enrollment in Pivotal Alzheimer’s Trial - TipRanks
Annovis Reaches Full Enrollment in Phase 3 Buntanetap Trial, 850 Patients Enrolled - TradingView
Annovis Bio (NYSE: ANVS) completes enrollment in 850-patient Phase 3 Alzheimer’s study - Stock Titan
Roth MKM Maintains Annovis Bio(ANVS.US) With Buy Rating, Maintains Target Price $8 - Moomoo
Analysts’ Top Healthcare Picks: Evolus (EOLS), Annovis Bio (ANVS) - The Globe and Mail
Annovis Promotes Research Chief as Lead Drug Nears Key Trial - MyChesCo
Annovis Bio Enrolls Over 850 Patients for Its Next Alzheimer's Disease Trial - Yahoo Finance
The timeline for the key clinical trial data readout of Annovis Bio Inc. has been clarified. - Bitget
Annovis Bio completes enrollment in phase 3 Alzheimer’s trial By Investing.com - Investing.com Australia
Annovis Bio Completes Patient Enrollment for Phase 3 Study of Buntanetap in Alzheimer's Disease - Moomoo
Annovis Bio completes enrollment in phase 3 Alzheimer’s trial - Investing.com
Annovis Reaches Full Enrollment in Pivotal Phase 3 Trial of Buntanetap for Early Alzheimer’s Disease - GlobeNewswire
The buntanetap programAnnovis Bio bets on neurodegeneration trials - ad-hoc-news.de
Annovis Bio promotes Cheng Fang to chief scientific officer By Investing.com - Investing.com Australia
Annovis Bio promotes Cheng Fang to chief scientific officer - Investing.com
Annovis Bio Promotes Cheng Fang to Chief Scientific Officer Ahead of Phase 3 Milestones - citybiz
Annovis Appoints Cheng Fang, Ph.D., as Chief Scientific Officer - The Manila Times
Press Release: Annovis Appoints Cheng Fang, Ph.D., as Chief Scientific Officer - Moomoo
ANVSAnnovis Bio Inc Latest SEC Filings - Finviz
ANVS Q1 2026 Earnings: Wider-than-Expected Loss as Pre-Revenue Biotech Advances PipelineAnalyst Consensus Shift - dars.gov.et
Annovis Bio, Inc.(NYSE: ANVS) added to Russell 3000E Growth Benchmark - marketscreener.com
Annovis Bio, Inc.(NYSE: ANVS) added to Russell 3000E Index - marketscreener.com
Annovis Bio, Inc.(NYSE: ANVS) added to Russell Microcap Index - marketscreener.com
ANVS Financials: Revenue Breakdown, Margins & Competitor Comparison - Intellectia AI
Annovis Bio, Inc.(NYSE: ANVS) added to Russell Microcap Growth Benchmark Index - marketscreener.com
Annovis Bio (ANVS) Shows Resilience With 4.24% Gain, Testing Key ResistanceBeta Neutral Pair - dars.gov.et
Annovis Bio | 144: Notice of proposed sale of securities pursuant to Rule 144 - Moomoo
Annovis Bio Inc Actuals & Estimates (TRADEGATE:07X) - TradingView
Annovis Bio | DEFA14A: Others - Moomoo
ANVS Forecast — Price Target — Prediction for 2027 - TradingView
Annovis Bio Inc Actuals & Estimates (FWB:07X) - TradingView
07X Forecast — Price Target — Prediction for 2027 - TradingView
Enterprise value to EBITDA forward of Annovis Bio, Inc. – NYSE:ANVS - TradingView
Price to sales forward of Annovis Bio, Inc. – NYSE:ANVS - TradingView
Enterprise value to revenue forward of Annovis Bio, Inc. – NYSE:ANVS - TradingView
Annovis Bio Q1 2026 Earnings: EPS Misses Wide Expectations as Pre-Revenue Biotech Advances PipelineLow Growth Earnings - DonanımHaber
Annovis Bio Inc (ANVS) Technical Analysis: Support, Resistance, Indicators & Moving Averages - TradingKey
ANVS Q1 2026 Earnings: Wider-than-Expected Loss Highlights Pre-Revenue Biotech ChallengesAnnual Report - DonanımHaber
Annovis Bio Shareholders Approve Governance and Compensation Changes - The Globe and Mail
Why Annovis’ buntanetap pill is drawing fresh attention in Alzheimer’s race - AD HOC NEWS
Annovis Bio Inc (ANVS) Valuation: PE, PB & Fair Value Analysis - TradingKey
Annovis Bio shareholders approve all proposals at annual meeting - Investing.com UK
Annovis Bio shareholders approve all proposals at annual meeting By Investing.com - Investing.com India
Annovis Bio Inc (ANVS) Earnings Forecast: Future EPS & Revenue Growth Estimates - TradingKey
Annovis Bio Inc (ANVS) Institutional Confidence - TradingKey
Annovis Bio Inc (ANVS) Financial Health: Profitability & Balance Sheet Analysis - TradingKey
Annovis Bio Inc (ANVS) Risk Assessment: Volatility, Financial Risk & Investment Risk - TradingKey
Annovis Bio (NYSE: ANVS) holders expand equity plan and set biennial say-on-pay - Stock Titan
Annovis Bio Inc (ANVS) Dividends & Stock Splits: Historical Payouts and Event Timeline - TradingKey
0.35%
大文字化:
|
ボリューム (24 時間):